2019
A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer
Segar, J. M., Reed, D., Stopeck, A. T., Livingston, R. B. & Chalasani, P., Jan 1 2019, (Accepted/In press) In : Oncologist.Research output: Contribution to journal › Article
Open Access
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer
Mehta, R. S., Barlow, W. E., Albain, K. S., Vandenberg, T. A., Dakhil, S. R., Tirumali, N. R., Lew, D. L., Hayes, D. F., Gralow, J. R., Linden, H. H., Livingston, R. B. & Hortobagyi, G. N., Mar 28 2019, In : New England Journal of Medicine. 380, 13, p. 1226-1234 9 p.Research output: Contribution to journal › Article
16
Scopus
citations
2018
Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci
Sucheston-Campbell, L. E., Clay-Gilmour, A. I., Barlow, W. E., Budd, G. T., Stram, D. O., Haiman, C. A., Sheng, X., Yan, L., Zirpoli, G., Yao, S., Jiang, C., Owzar, K., Hershman, D., Albain, K. S., Hayes, D. F., Moore, H. C., Hobday, T. J., Stewart, J. A., Rizvi, A., Isaacs, C. & 6 others, , Jan 1 2018, In : Pharmacogenetics and Genomics. 28, 2, p. 49-55 7 p.Research output: Contribution to journal › Article
7
Scopus
citations
2016
Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer
Brown-Glaberman, U., Marron, M., Chalasani, P., Livingston, R. B., Iannone, M. E., Specht, J. & Stopeck, A. T., 2016, In : Disease Markers. 2016, 9810383.Research output: Contribution to journal › Article
7
Scopus
citations
Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226
Hertz, D. L., Barlow, W. E., Kidwell, K. M., Albain, K. S., Vandenberg, T. A., Dakhil, S. R., Tirumali, N. R., Livingston, R. B., Gralow, J., Hayes, D. F., Hortobagyi, G. N., Mehta, R. S. & Rae, J. M., 2016, (Accepted/In press) In : British Journal of Clinical Pharmacology.Research output: Contribution to journal › Article
10
Scopus
citations
Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630
Potkul, R. K., Unger, J. M., Livingston, R. B., Crew, K. D., Wilczynski, S. P., Salomon, C. G., Smith, B. L., Wong, L., Campbell, D. L., Einspahr, D. E., Anderson, G. L., Hershman, D., Goodman, G. E., Brown, P. H., Meyskens, F. L. & Albain, K. S., Dec 14 2016, In : npj Breast Cancer. 2, 1, 16024.Research output: Contribution to journal › Article
3
Scopus
citations
SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer
Nahleh, Z. A., Barlow, W. E., Hayes, D. F., Schott, A. F., Gralow, J. R., Sikov, W. M., Perez, E. A., Chennuru, S., Mirshahidi, H. R., Corso, S. W., Lew, D. L., Pusztai, L., Livingston, R. B. & Hortobagyi, G. N., Aug 1 2016, In : Breast Cancer Research and Treatment. 158, 3, p. 485-495 11 p.Research output: Contribution to journal › Article
42
Scopus
citations
Temporal heterogeneity of estrogen receptor expression in bone-dominant breast cancer: 18f-fluoroestradiol pet imaging shows return of er expression
Currin, E., Peterson, L. M., Schubert, E. K., Link, J. M., Krohn, K. A., Livingston, R. B., Mankoff, D. A. & Linden, H. M., Feb 1 2016, In : JNCCN Journal of the National Comprehensive Cancer Network. 14, 2, p. 144-147 4 p.Research output: Contribution to journal › Article
5
Scopus
citations